Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00153101
First received: September 9, 2005
Last updated: May 13, 2014
Last verified: May 2014
  Purpose

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.


Condition Intervention Phase
Cardiovascular Diseases
Drug: Telmisartan
Drug: Combination of Telmisartan and Ramipril
Drug: Ramipril
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Prevention
Official Title: ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.

  • ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients [ Time Frame: 56 months ] [ Designated as safety issue: No ]

    ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

    These renal outcomes were not adjudicated (apart from death).


  • TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.


Secondary Outcome Measures:
  • ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the following defined endpoints, non-fatal myocardial infarction or non-fatal stroke

  • ONTARGET. Cardiovascular Death [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint cardiovascular death.

  • ONTARGET. Non-fatal Myocardial Infarction [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint non-fatal myocardial infarction.

  • ONTARGET. Non-fatal Stroke [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint non-fatal stroke.

  • ONTARGET. Hospitalization for Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint hospitalization for congestive heart failure.

  • ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

  • ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ESRD is defined by initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m². Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

  • ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Diabetic nephropathy patients are diabetic patients with macro-albuminuria assessed as a Urinary Albumin Creatinine Ratio (UACR) ≥300 mg/g Crea at baseline.

  • ONTARGET. Doubling of Serum Creatinine [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: doubling of serum creatinine

  • ONTARGET. Progression to ESRD [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73 m².

  • ONTARGET. New Microalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥30 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <30 mg/g Crea at baseline.

  • ONTARGET. New Macroalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as Urinary Albumin Creatinine Ratio ≥300 mg/g Crea in patients with a Urinary Albumin Creatinine Ratio <300 mg/g Crea at baseline.

  • ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: Combined endpoint of doubling of serum creatinine, progression to ESRD, new microalbuminuria, or new macroalbuminuria

  • ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    ONTARGET. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.

  • ONTARGET. Newly Diagnosed Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Congestive Heart failure.

  • ONTARGET. Cardiovascular Revascularization Procedure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET).

  • ONTARGET. Newly Diagnosed Diabetes [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.

  • ONTARGET. Cognitive Decline [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.

  • ONTARGET. New Onset of Atrial Fibrillation [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    The Ongoing Telmisartan Alone and combination with Ramipril global Endpoint trial (ONTARGET). Time to first event analysis of endpoint new onset of atrial fibrillation.

  • TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the following defined endpoints, Cardiovascular Death, Non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure.

  • TRANSCEND. Cardiovascular Death [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint cardiovascular death.

  • TRANSCEND. Non-fatal Myocardial Infarction [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint non-fatal myocardial infarction.

  • TRANSCEND. Non-fatal Stroke [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

  • TRANSCEND. Hospitalization for Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

  • TRANSCEND. Doubling of Serum Creatinine [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: doubling of serum creatinine

  • TRANSCEND. Progression to ESRD [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: Progression to ESRD. Progression to ESRD is defined as initiation of dialysis, need for renal transplantation, or eGFR <15 mL/min/1.73m²

  • TRANSCEND. New Microalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: New microalbuminuria. New microalbuminuria is defined as UACR ≥30 mg/g creatinine [Crea] in patients with a UACR <30 mg/g Crea at baseline

  • TRANSCEND. New Macroalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: New macroalbuminuria. New macroalbuminuria is defined as UACR ≥300 mg/g creatinine [Crea] in patients with a UACR <300 mg/g Crea at baseline

  • TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: Combined endpoint of doubling serum creatinine, progression to ESRD, new microalbuminuria or new macroalbuminuria

  • TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    TRANSCEND. Nephropathy subcategory: Normalisation from micro- or macroalbuminuria to normoalbuminuria. Normalisation from micro- or macroalbuminuria to normoalbuminuria is defined as UACR <30 mg/g Crea in patients with a UACR ≥30 mg/g Crea at baseline.

  • TRANSCEND. New Onset of Atrial Fibrillation [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

  • TRANSCEND. Cognitive Decline [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to first event analysis of the endpoint cognitive decline i.e. Comparison of the Mini mental state Evaluation (MMSE) of patients at baseline with that at the 2years and end of trial. A decrease in MMSE from baseline represents a cognitive decline. This outcome measure is only available for those patients who had MMSE at baseline.

  • TRANSCEND. Newly Diagnosed Diabetes [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND). Time to the first event analysis of the endpoint Newly diagnosed Diabetes. Only calculated for those patients without diabetes at baseline.

  • TRANSCEND. Cardiovascular Revascularization Procedure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).

  • TRANSCEND. Newly Diagnosed Congestive Heart Failure [ Time Frame: 56 months ] [ Designated as safety issue: No ]
    Telmisartan Randomized Assessment Study in Angiotension Converting Enzyme inhibitor intolerant subjects with cardiovascular disease (TRANSCEND).


Enrollment: 31546
Study Start Date: November 2001
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Coronary Artery Disease: Previous Myocardial infarction(> 2 days prior to informed consent), or stable or previous unstable angina (> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed > 4 years prior to informed consent) or with recurrent angina after surgery.

Other High Risk:

  1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio < 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
  2. Previous stroke
  3. Transient ischemic Attack > 7 days and < 1 year prior to informed consent
  4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.

No definite and specific indication or contraindication for any of the study treatments. Written informed consent.

Exclusion Criteria:

A. Medication use:

  1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
  2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.

NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.

B. Cardiovascular disease:

  1. Symptomatic congestive heart failure.
  2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
  3. Constrictive pericarditis.
  4. Complex congenital heart disease.
  5. Syncopal episodes of unknown etiology < 3 months before informed consent.
  6. Planned cardiac surgery or angioplasty within three months.
  7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) > 160/100).
  8. Heart transplant recipient.
  9. Strokes due to subarachnoid hemorrhage

C. Other conditions:

  1. Significant renal disease defined as:

    1. Renal artery stenosis;
    2. Creatinine clearance < 0.6 ml/min or serum creatinine > 265 umol/L (> 3.0 mg/dL);
    3. Hyperkalemia: potassium > 5.5 mmol/L.
    4. Proteinuria* (for TRANSCEND only).
  2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) > than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin > 20 umol/L, biliary obstructive disorders.
  3. Uncorrected volume depletion or sodium depletion.
  4. Primary aldosteronism.
  5. Hereditary fructose intolerance.
  6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
  7. Patient is simultaneously taking another experimental drug.
  8. Patient with significant disability that precludes regular attendance at clinic for follow-up.
  9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
  10. Unable or unwilling to provide written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00153101

  Hide Study Locations
Locations
United States, Alabama
502.373.0256 Boehringer Ingelheim Investigational Site
Athens, Alabama, United States
502.373.0251 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
United States, Arizona
502.373.0188 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
502.373.0182 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
502.373.0189 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
502.373.0177 Boehringer Ingelheim Investigational Site
Tuscon, Arizona, United States
United States, Arkansas
502.373.0209 Boehringer Ingelheim Investigational Site
Bentonville, Arkansas, United States
United States, California
502.373.0173 Boehringer Ingelheim Investigational Site
Concord, California, United States
502.373.0266 Boehringer Ingelheim Investigational Site
Harbor City, California, United States
502.373.0283 Boehringer Ingelheim Investigational Site
Loma Linda, California, United States
502.373.0180 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
502.373.0175 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
502.373.0165 Boehringer Ingelheim Investigational Site
San Diego, California, United States
502.373.0228 Boehringer Ingelheim Investigational Site
San Leandro, California, United States
502.373.0205 Boehringer Ingelheim Investigational Site
Sylmar, California, United States
502.373.0277 Boehringer Ingelheim Investigational Site
West Hills, California, United States
United States, Connecticut
502.373.0226 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
502.373.0174 Boehringer Ingelheim Investigational Site
Farmington, Connecticut, United States
United States, District of Columbia
502.373.0258 Boehringer Ingelheim Investigational Site
Washington, District of Columbia, United States
United States, Florida
502.373.0179 Boehringer Ingelheim Investigational Site
Gainesville, Florida, United States
502.373.0183 Boehringer Ingelheim Investigational Site
Palm Harbor, Florida, United States
502.373.0240 Boehringer Ingelheim Investigational Site
Panama City, Florida, United States
502.373.0171 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
502.373.0282 Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
502.373.0214 Boehringer Ingelheim Investigational Site
Weston, Florida, United States
United States, Georgia
502.373.0193 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0161 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0201 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
502.373.0223 Boehringer Ingelheim Investigational Site
Conyers, Georgia, United States
502.373.0268 Boehringer Ingelheim Investigational Site
Sandersville, Georgia, United States
502.373.0245 Boehringer Ingelheim Investigational Site
Savannah, Georgia, United States
502.373.0199 Boehringer Ingelheim Investigational Site
Tucker, Georgia, United States
502.373.0162 Boehringer Ingelheim Investigational Site
Valdosta, Georgia, United States
United States, Idaho
502.373.0203 Boehringer Ingelheim Investigational Site
Pocatello, Idaho, United States
United States, Illinois
502.373.0244 Boehringer Ingelheim Investigational Site
Burbank, Illinois, United States
502.373.0272 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
502.373.0217 Boehringer Ingelheim Investigational Site
Olympia Fields, Illinois, United States
United States, Iowa
502.373.0270 Boehringer Ingelheim Investigational Site
Des Moines, Iowa, United States
United States, Louisiana
502.373.0167 Boehringer Ingelheim Investigational Site
Monroe, Louisiana, United States
502.373.0158 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
United States, Maryland
502.373.0247 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
United States, Massachusetts
502.373.0284 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
502.373.0229 Boehringer Ingelheim Investigational Site
Springfield, Massachusetts, United States
United States, Michigan
502.373.0237 Boehringer Ingelheim Investigational Site
Wyandotte, Michigan, United States
United States, Minnesota
502.373.0208 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
502.373.0232 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
502.373.0231 Boehringer Ingelheim Investigational Site
St. Paul, Minnesota, United States
United States, Mississippi
502.373.0181 Boehringer Ingelheim Investigational Site
Biloxi, Mississippi, United States
502.373.0185 Boehringer Ingelheim Investigational Site
Cleveland, Mississippi, United States
502.373.0254 Boehringer Ingelheim Investigational Site
Jackson, Mississippi, United States
United States, Missouri
502.373.0195 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
502.373.0207 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
502.373.0239 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, Nebraska
502.373.0279 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, Nevada
502.373.0169 Boehringer Ingelheim Investigational Site
North Las Vegas, Nevada, United States
United States, New Jersey
502.373.0157 Boehringer Ingelheim Investigational Site
Camden, New Jersey, United States
502.373.0202 Boehringer Ingelheim Investigational Site
East Orange, New Jersey, United States
502.373.0191 Boehringer Ingelheim Investigational Site
Newark, New Jersey, United States
502.373.0271 Boehringer Ingelheim Investigational Site
Westwood, New Jersey, United States
United States, New York
502.373.0150 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
502.373.0213 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
502.373.0230 Boehringer Ingelheim Investigational Site
Buffalo, New York, United States
502.373.0288 Boehringer Ingelheim Investigational Site
Kingston, New York, United States
502.373.0252 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0286 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0238 Boehringer Ingelheim Investigational Site
New York, New York, United States
502.373.0166 Boehringer Ingelheim Investigational Site
Northport, New York, United States
502.373.0156 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
502.373.0264 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
502.373.0227 Boehringer Ingelheim Investigational Site
Scarsdale, New York, United States
502.373.0163 Boehringer Ingelheim Investigational Site
Westfield, New York, United States
502.373.0241 Boehringer Ingelheim Investigational Site
Williamsville, New York, United States
United States, North Carolina
502.373.0273 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States
502.373.0261 Boehringer Ingelheim Investigational Site
Winston Salem, North Carolina, United States
United States, North Dakota
502.373.0222 Boehringer Ingelheim Investigational Site
Fargo, North Dakota, United States
United States, Ohio
502.373.0155 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
502.373.0164 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
502.373.0168 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
502.373.0159 Boehringer Ingelheim Investigational Site
Mansfield, Ohio, United States
502.373.0178 Boehringer Ingelheim Investigational Site
Oklahoma City, Ohio, United States
United States, Oklahoma
502.373.0259 Boehringer Ingelheim Investigational Site
Guthrie, Oklahoma, United States
502.373.0154 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
502.373.0152 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
United States, Oregon
502.373.0243 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
502.373.0265 Boehringer Ingelheim Investigational Site
Erie, Pennsylvania, United States
502.373.0153 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
502.373.0274 Boehringer Ingelheim Investigational Site
Sellersville, Pennsylvania, United States
United States, South Carolina
502.373.0184 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
502.373.0248 Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
United States, Texas
502.373.0172 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0219 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0187 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0275 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
502.373.0221 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
502.373.0206 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
502.373.0234 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
502.373.0280 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
United States, Virginia
502.373.0249 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
United States, Washington
502.373.0281 Boehringer Ingelheim Investigational Site
Seattle, Washington, United States
United States, Wisconsin
502.373.0212 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
Argentina
502.373.378 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.350 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.351 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.352 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.353 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.354 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.355 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.356 Boehringer Ingelheim Investigational Site
Capital Federal, Argentina
502.373.362 Boehringer Ingelheim Investigational Site
Corones Suárez, Argentina
502.373.357 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.358 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.360 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.361 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.377 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
502.373.364 Boehringer Ingelheim Investigational Site
La Plata, Argentina
502.373.365 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
502.373.376 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
502.373.366 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
502.373.367 Boehringer Ingelheim Investigational Site
Rosario, Argentina
502.373.369 Boehringer Ingelheim Investigational Site
Salta, Argentina
502.373.375 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
502.373.371 Boehringer Ingelheim Investigational Site
Tucumán, Argentina
502.373.373 Boehringer Ingelheim Investigational Site
Tucumán, Argentina
502.373.374 Boehringer Ingelheim Investigational Site
Zárate, Argentina
Australia, Australian Capital Territory
502.373.0534 The Canberra Hospital
Woden, Australian Capital Territory, Australia
Australia, New South Wales
502.373.0536 Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
502.373.0544 Coffs Harbour Cardiovascular Clinic
Coffs Harbour, New South Wales, Australia
502.373.0538 Concord Repatriation General Hospital
Concord, New South Wales, Australia
502.373.0539 Central Coast Neuroscience Research
Gosford, New South Wales, Australia
502.373.0556 Gosford Hospital
Gosford, New South Wales, Australia
502.373.0552 St George Private Hospital
Kogarah, New South Wales, Australia
502.373.0542 St. George Hospital
Kogarah, New South Wales, Australia
502.373.0559 St George Hospital - Dept of Clinical Pharmacology
Kogarah, New South Wales, Australia
502.373.0528 John Hunter Hospital
Newcastle, New South Wales, Australia
502.373.0535 The Prince of Wales Hospital
Randwick, New South Wales, Australia
502.373.0533 Royal North Shore Hospital
St Leonards, New South Wales, Australia
502.373.0549 Illawarra Regional Hospital
Wollongong, New South Wales, Australia
Australia, Queensland
502.373.0523 The Prince Charles Hospital
Chermside, Queensland, Australia
502.373.0524 Royal Brisbane Hospital
Herston, Queensland, Australia
502.373.0526 Peninsula Clinical Research Centre
Kippa-Ring, Queensland, Australia
502.373.0540 Gold Coast Hospital
Southport, Queensland, Australia
502.373.0521 Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Australia, South Australia
502.373.0546 Flinders Medical Centre
Bedford Park, South Australia, Australia
502.373.0550 Repatriation General Hospital
Daw Park, South Australia, Australia
502.373.0551 Port Lincoln "The Investigator" Clinic
Port Lincoln, South Australia, Australia
Australia, Tasmania
502.373.0529 Launceston General Hospital
Launceston, Tasmania, Australia
Australia, Victoria
502.373.0531 Box Hill Hospital
Box Hill, Victoria, Australia
502.373.0548 The Northern Hospital
Epping, Victoria, Australia
502.373.0522 The Geelong Hospital
Geelong, Victoria, Australia
502.373.0520 Royal Melbourne Hospital
Parkville, Victoria, Australia
502.373.0525 The Alfred Hospital
Prahran, Victoria, Australia
502.373.0532 Baker Medical Research Centre
Prahran, Victoria, Australia
502.373.0557 Maroondah Hospital
Ringwood East, Victoria, Australia
502.373.0537 Austin & Repatriation Medical Centre
West Heidelberg, Victoria, Australia
Australia, Western Australia
502.373.0547 Fremantle Hospital
Fremantle, Western Australia, Australia
502.373.0530 Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
502.373.0545 Royal Perth Hospital
Perth, Western Australia, Australia
Austria
502.373.1128 Boehringer Ingelheim Investigational Site
Graz, Austria
502.373.1125 Boehringer Ingelheim Investigational Site
Wels, Austria
502.373.1129 Boehringer Ingelheim Investigational Site
Wien, Austria
502.373.1126 Boehringer Ingelheim Investigational Site
Wien, Austria
502.373.1127 Boehringer Ingelheim Investigational Site
Wien, Austria
Belgium
502.373.1004 Boehringer Ingelheim Investigational Site
Aalst, Belgium
502.373.1015 Boehringer Ingelheim Investigational Site
Anderlecht, Belgium
502.373.1005 Boehringer Ingelheim Investigational Site
Antwerpen, Belgium
502.373.1022 Boehringer Ingelheim Investigational Site
Bornem, Belgium
502.373.1021 Boehringer Ingelheim Investigational Site
Brasschaat, Belgium
502.373.1003 Boehringer Ingelheim Investigational Site
Brugge, Belgium
502.373.1017 Boehringer Ingelheim Investigational Site
Charleroi, Belgium
502.373.1009 Boehringer Ingelheim Investigational Site
Genk, Belgium
502.373.1018 Boehringer Ingelheim Investigational Site
Godinne, Belgium
502.373.1019 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul, Belgium
502.373.1011 Boehringer Ingelheim Investigational Site
Haine-Saint-Paul, Belgium
502.373.1007 Boehringer Ingelheim Investigational Site
Hasselt, Belgium
502.373.1000 Boehringer Ingelheim Investigational Site
Leuven, Belgium
502.373.1020 Boehringer Ingelheim Investigational Site
Mechelen, Belgium
502.373.1006 Boehringer Ingelheim Investigational Site
Mol, Belgium
502.373.1028 Boehringer Ingelheim Investigational Site
Roeselare, Belgium
502.373.1014 Boehringer Ingelheim Investigational Site
Seraing, Belgium
502.373.1010 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
502.373.1002 Boehringer Ingelheim Investigational Site
Turnhout, Belgium
502.373.1025 Boehringer Ingelheim Investigational Site
Woluwé-Saint-Lambert, Belgium
Brazil
502.373.405 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.426 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.412 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
502.373.418 Boehringer Ingelheim Investigational Site
Botucatu -, Brazil
502.373.407 Boehringer Ingelheim Investigational Site
Campinas, Brazil
502.373.419 Boehringer Ingelheim Investigational Site
Campinas, Brazil
502.373.425 Boehringer Ingelheim Investigational Site
Cerqueira César - São Paulo, Brazil
502.373.406 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
502.373.411 Boehringer Ingelheim Investigational Site
Goiania, Brazil
502.373.403 Boehringer Ingelheim Investigational Site
Marília, Brazil
502.373.400 Boehringer Ingelheim Investigational Site
Pelotas, Brazil
502.373.417 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
502.373.416 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
502.373.415 Boehringer Ingelheim Investigational Site
Porto Alegre - Rs, Brazil
502.373.420 Boehringer Ingelheim Investigational Site
Ribeirao Preto, Brazil
502.373.414 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
502.373.413 Boehringer Ingelheim Investigational Site
Rio de Janeiro - Rj, Brazil
502.373.410 Boehringer Ingelheim Investigational Site
Salvador, Brazil
502.373.409 Boehringer Ingelheim Investigational Site
Salvador, Brazil
502.373.404 Boehringer Ingelheim Investigational Site
Santa Catalina, Brazil
502.373.421 Boehringer Ingelheim Investigational Site
Sao Jose do Rio Preto, Brazil
502.373.422 Boehringer Ingelheim Investigational Site
Sao Paulo, Brazil
502.373.408 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.424 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.402 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
502.373.423 Boehringer Ingelheim Investigational Site
Vila Clementino, São Paulo, Brazil
Canada, Alberta
502.373.0001 C849 Division of Cardiology, Foothills Medical Centre
Calgary, Alberta, Canada
502.373.0071 Peter Lougheed Centre
Calgary, Alberta, Canada
502.373.0020 CHA/University Hospital
Edmonton, Alberta, Canada
Canada, British Columbia
502.373.0073 Alder Medical Centre
Campbell river, British Columbia, Canada
502.373.0062 Gain Medical Centre
Coquitlam, British Columbia, Canada
502.373.0046 Interior Clinical Research Consultants Ltd
Kelowna, British Columbia, Canada
502.373.0038 New West Cardiac Research
New Westminster, British Columbia, Canada
502.373.0048 Suite 100
North Vancouver, British Columbia, Canada
502.373.0002 Penticton Regional Hospital
Penticton, British Columbia, Canada
502.373.0009 Vancouver Hospital
Vancouver, British Columbia, Canada
502.373.0003 Discovery Clinical Services Ltd
Victoria, British Columbia, Canada
Canada, Manitoba
502.373.0050 St. Pierre Medical Clinic
St. Pierre, Manitoba, Canada
502.373.0077 Health Science Centre Diabetes Research Group
Winnipeg, Manitoba, Canada
Canada, Newfoundland and Labrador
502.373.0005 Dr. Jeffrey Hiscock
ST John's, Newfoundland and Labrador, Canada
502.373.0006 The General Hospital
St. John's, Newfoundland and Labrador, Canada
Canada, Nova Scotia
502.373.0056 Antigonish Clinical Trials
Antigonish, Nova Scotia, Canada
502.373.0045 Queen Elizabeth II HSC
Halifax, Nova Scotia, Canada
Canada, Ontario
502.373.0031 Brampton Research Associates
Brampton, Ontario, Canada
502.373.0082 3U4, McMaster University Medical Centre
Hamilton, Ontario, Canada
502.373.0085 HGH McMaster Clinic
Hamilton, Ontario, Canada
502.373.0011 St. Joseph's Hospital Cardiac Research
Hamilton, Ontario, Canada
502.373.0064 Chedoke Hospital
Hamilton, Ontario, Canada
502.373.0035 Hamilton Medical Research
Hamilton, Ontario, Canada
502.373.0034 HGH McMaster Clinic
Hamilton, Ontario, Canada
502.373.0024 London HSC - University Hospital
London, Ontario, Canada
502.373.0044 Mississauga Clinical Research Centre
Mississauga, Ontario, Canada
502.373.0043 Fraser Clinical Trial Inc
New Westminster, Ontario, Canada
502.373.0032 New Market Cardiology Research Grp
Newmarket, Ontario, Canada
502.373.0037 Niagara Falls Medical Centre
Niagara Falls, Ontario, Canada
502.373.0054 Orleans Medical-Dental Centre
Orleans, Ontario, Canada
502.373.0063 Paradigm Clinical Trials
Oshawa, Ontario, Canada
502.373.0058 Medical Sciences Building
Oshawa, Ontario, Canada
502.373.0051 Merivale Cardiovascular Consultants
Ottawa, Ontario, Canada
502.373.0029 Riverside Professional Building
Ottawa, Ontario, Canada
502.373.0040 Etobicok Cardiology
Rexdale, Ontario, Canada
502.373.0023 Group Health Centre - Clinical Trials
Sault Ste Marie, Ontario, Canada
502.373.0039 Scarborough Cardiology Research
Scarborough, Ontario, Canada
502.373.0007 Sudbury Cardiac Research
Sudbury, Ontario, Canada
502.373.0061 CLIKS Medical Research Corp
Thunder Bay, Ontario, Canada
502.373.0083 St. Michael's Hospital
Toronto, Ontario, Canada
502.373.0042 Sunnybrook & Woman's College Health Science Centre
Toronto, Ontario, Canada
502.373.0052 Dr. Bruce Lubelsky
Willowdale, Ontario, Canada
502.373.0008 Windsor Health Clinic
Windsor, Ontario, Canada
Canada, Quebec
502.373.0081 Centre de recherche clinique, CUSE 3001
Fleurimont, Quebec, Canada
502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau
Gatineau, Quebec, Canada
502.373.0057 Centre De Recherche Clinique
Laval, Quebec, Canada
502.373.0033 Clinique de Cardiologie de Levis
Levis, Quebec, Canada
502.373.0086 Via Car Recherche Clinique Inc
Longueuil, Quebec, Canada
502.373.0013 Suite 170
Longueuil, Quebec, Canada
502.373.0010 Recherche Invascor
Longueuil, Quebec, Canada
502.373.0016 Suite 170
Longueuil, Quebec, Canada
502.373.0014 Via Car Recherche Clinique Inc
Longueuil, Quebec, Canada
502.373.0015 C/O Peter Carmichael
Longueuil, Quebec, Canada
502.373.0017 Suite 170
Longueuil, Quebec, Canada
502.373.0022 CHUM - Hotel Dieu
Montreal, Quebec, Canada
502.373.0025 Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada
502.373.0021 Medi - recherche Inc.
Montreal, Quebec, Canada
502.373.0018 Montreal Heart Institute
Montreal, Quebec, Canada
502.373.0079 Jewish General Hospital
Montreal, Quebec, Canada
502.373.0027 Ctr Hospitalier Beauce Etchemin
St George de Beauce, Quebec, Canada
502.373.0012 Hopital Laval - Institute Cardiologie de Quebec
Ste-Foy, Quebec, Canada
502.373.0026 Centre hospitalier Pierre-Le Gardeur
Terrebonne, Quebec, Canada
502.373.0072 Chra
Thetford Mines, Quebec, Canada
Canada, Saskatchewan
502.373.0067 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0053 Mount Royal Clinic
Saskatoon, Saskatchewan, Canada
502.373.0068 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0055 Specialists - Internal Medicine
Saskatoon, Saskatchewan, Canada
502.373.0070 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
502.373.0066 SDRI - University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Canada
502.373.0030 Portage Clinical Studies
Manitoba, Canada
502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de
Quebec, Canada
502.373.0084 CHA-Hopital de l'Efant-Jesus
Quebec, Canada
502.373.0028 Hop. Du St. Sacrement
Quebec, Canada
502.373.0041 Recherches Clinicar Inc.
Quebec, Canada
China
502.373.0606 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0602 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0603 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0623 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0605 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0607 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0601 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0604 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0621 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0622 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0626 Boehringer Ingelheim Investigational Site
Beijing, China
502.373.0616 Boehringer Ingelheim Investigational Site
Changsha, China
502.373.0613 Boehringer Ingelheim Investigational Site
Chengdu, China
502.373.0625 Boehringer Ingelheim Investigational Site
Chengdu, China
502.373.0620 Boehringer Ingelheim Investigational Site
Guangzhou, China
502.373.0612 Boehringer Ingelheim Investigational Site
Harbin, China
502.373.0634 Boehringer Ingelheim Investigational Site
HeBei Province, China
502.373.0624 Boehringer Ingelheim Investigational Site
Henan Province, China
502.373.0627 Boehringer Ingelheim Investigational Site
Hubei Province, China
502.373.0614 Boehringer Ingelheim Investigational Site
Nanjing, China
502.373.0629 Boehringer Ingelheim Investigational Site
QingDao, China
502.373.0632 Boehringer Ingelheim Investigational Site
ShanDong Province, China
502.373.0633 Boehringer Ingelheim Investigational Site
ShanDong Province, China
502.373.0618 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0617 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0619 Boehringer Ingelheim Investigational Site
Shanghai, China
502.373.0628 Boehringer Ingelheim Investigational Site
Shen Yang, China
502.373.0611 Boehringer Ingelheim Investigational Site
Shijiazhuang, China
502.373.0631 Boehringer Ingelheim Investigational Site
Tianjin, China
502.373.0615 Boehringer Ingelheim Investigational Site
Tianjin, China
502.373.0630 Boehringer Ingelheim Investigational Site
Weizikeng, China
502.373.0608 Boehringer Ingelheim Investigational Site
Wuhan, China
502.373.0610 Boehringer Ingelheim Investigational Site
Zhenzhou, China
Czech Republic
502.373.1053 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
502.373.1060 Boehringer Ingelheim Investigational Site
Havirov, Czech Republic
502.373.1055 Boehringer Ingelheim Investigational Site
Kladno, Czech Republic
502.373.1059 Boehringer Ingelheim Investigational Site
Mlada Boleslav, Czech Republic
502.373.1061 Boehringer Ingelheim Investigational Site
Plzen, Czech Republic
502.373.1057 Boehringer Ingelheim Investigational Site
Prague, Czech Republic
502.373.1051 Boehringer Ingelheim Investigational Site
Prague 5, Czech Republic
502.373.1062 Boehringer Ingelheim Investigational Site
Praha 2, Czech Republic
502.373.1056 Boehringer Ingelheim Investigational Site
Pribram 1, Czech Republic
502.373.1058 Boehringer Ingelheim Investigational Site
Usti nad Orlici, Czech Republic
Denmark
502.373.1450 Boehringer Ingelheim Investigational Site
Aalborg, Denmark
502.373.1453 Boehringer Ingelheim Investigational Site
Aarhus C, Denmark
502.373.1455 Boehringer Ingelheim Investigational Site
Frederiksberg, Denmark
502.373.1459 Boehringer Ingelheim Investigational Site
Frederiksberg C, Denmark
502.373.1460 Boehringer Ingelheim Investigational Site
Helsingoer, Denmark
502.373.1458 Boehringer Ingelheim Investigational Site
Hilleroed, Denmark
502.373.1451 Boehringer Ingelheim Investigational Site
Holbaek, Denmark
502.373.1452 Boehringer Ingelheim Investigational Site
Hvidovre, Denmark
502.373.1461 Boehringer Ingelheim Investigational Site
Kjellerup, Denmark
502.373.1456 Boehringer Ingelheim Investigational Site
Randers, Denmark
502.373.1457 Boehringer Ingelheim Investigational Site
Slagelse, Denmark
502.373.1454 Boehringer Ingelheim Investigational Site
Svendborg, Denmark
Finland
502.373.1473 Boehringer Ingelheim Investigational Site
Helsinki, Finland
502.373.1470 Boehringer Ingelheim Investigational Site
Helsinki, Finland
502.373.1486 Boehringer Ingelheim Investigational Site
Hämeenlinna, Finland
502.373.1479 Boehringer Ingelheim Investigational Site
Jyväskylä, Finland
502.373.1488 Boehringer Ingelheim Investigational Site
Kuopio, Finland
502.373.1481 Boehringer Ingelheim Investigational Site
Kuusankoski, Finland
502.373.1487 Boehringer Ingelheim Investigational Site
Liperi, Finland
502.373.1475 Boehringer Ingelheim Investigational Site
Oulun kaupunki, Finland
502.373.1471 Boehringer Ingelheim Investigational Site
Turku, Finland
502.373.1485 Boehringer Ingelheim Investigational Site
Vantaa, Finland
France
502.373.1093 Cabinet Médical
Albens, France
502.373.1090 Cabinet Médical
Beziers, France
502.373.1075 Cabinet Médical
Bourges, France
502.373.1091 Cabinet Médical
Broglie, France
502.373.1097 Cabinet Médical
Castelnaudary, France
502.373.1089 Cabinet Médical
Gemenos, France
502.373.1099 Cabinet Médical
Husseren Wesserlin, France
502.373.1094 Cabinet Médical
Hyeres, France
502.373.1078 Cabinet Médical des Tanneurs
L'Aigle, France
502.373.1096 Cabinet Médical
La Rochelle, France
502.373.1081 Cabinet Médical
Le Pradet, France
502.373.1083 Cabinet Médical
Murs Erigne, France
502.373.1086 Cabinet Médical
Nantes, France
502.373.1084 Cabinet Médical
Nantes, France
502.373.1080 Cabinet Médical
Niort, France
502.373.1095 Cabinet Médical
Ortez, France
502.373.1079 Cabinet Médical
Paris, France
502.373.1088 Cabinet Médical
Rennes, France
502.373.1098 Cabinet Médical
Rosiers d'Egletons, France
502.373.1085 Cabinet Médical
Saint Julien des Landes, France
502.373.1076 Cabinet Médical La Grande Ramée
Saint Martin dHyeres, France
502.373.1092 Cabinet Médical de St Pierre
Saint Pierre de Chandieu, France
502.373.1077 Cabinet Médical
Saint Romain sur Cher, France
502.373.1087 Cabinet Médical
Strasbourg, France
502.373.1082 Cabinet Médical
Tours, France
Germany
502.373.1164 Boehringer Ingelheim Investigational Site
Bad Lausick, Germany
502.373.1166 Boehringer Ingelheim Investigational Site
Bad Lauterberg, Germany
502.373.1138 Boehringer Ingelheim Investigational Site
Bad Mergentheim, Germany
502.373.1161 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1156 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1160 Boehringer Ingelheim Investigational Site
Berlin, Germany
502.373.1144 Boehringer Ingelheim Investigational Site
Bielefeld, Germany
502.373.1152 Boehringer Ingelheim Investigational Site
Dessau, Germany
502.373.1139 Boehringer Ingelheim Investigational Site
Dortmund, Germany
502.373.1159 Boehringer Ingelheim Investigational Site
Dortmund, Germany
502.373.1136 Boehringer Ingelheim Investigational Site
Dresden, Germany
502.373.1145 Boehringer Ingelheim Investigational Site
Eberswalde, Germany
502.373.1155 Boehringer Ingelheim Investigational Site
Erlangen, Germany
502.373.1157 Boehringer Ingelheim Investigational Site
Essen, Germany
502.373.1153 Boehringer Ingelheim Investigational Site
Haag, Germany
502.373.1148 Boehringer Ingelheim Investigational Site
Hamburg, Germany
502.373.1132 Boehringer Ingelheim Investigational Site
Heidelberg, Germany
502.373.1131 Boehringer Ingelheim Investigational Site
Homburg/Saar, Germany
502.373.1147 Boehringer Ingelheim Investigational Site
Karlsburg, Germany
502.373.1154 Boehringer Ingelheim Investigational Site
Kelkheim, Germany
502.373.1137 Boehringer Ingelheim Investigational Site
Köln, Germany
502.373.1142 Boehringer Ingelheim Investigational Site
Künzing, Germany
502.373.1165 Boehringer Ingelheim Investigational Site
Lübeck, Germany
502.373.1134 Boehringer Ingelheim Investigational Site
Mainz, Germany
502.373.1133 Boehringer Ingelheim Investigational Site
Melsungen, Germany
502.373.1146 Boehringer Ingelheim Investigational Site
München, Germany
502.373.1149 Boehringer Ingelheim Investigational Site
Offenbach am Main, Germany
502.373.1162 Boehringer Ingelheim Investigational Site
Riesa, Germany
502.373.1140 Boehringer Ingelheim Investigational Site
Rostock, Germany
502.373.1150 Boehringer Ingelheim Investigational Site
Sindelfingen, Germany
502.373.1163 Boehringer Ingelheim Investigational Site
Starnberg, Germany
502.373.1158 Boehringer Ingelheim Investigational Site
Stuttgart, Germany
502.373.1167 Boehringer Ingelheim Investigational Site
Timmendorfer Strand, Germany
502.373.1135 Boehringer Ingelheim Investigational Site
Wiesbaden, Germany
502.373.1141 Boehringer Ingelheim Investigational Site
Witten, Germany
Greece
502.373.1208 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1206 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1214 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1200 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1203 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1207 Boehringer Ingelheim Investigational Site
Athens, Greece
502.373.1209 Boehringer Ingelheim Investigational Site
Elefsina, Greece
502.373.1211 Boehringer Ingelheim Investigational Site
Goudi/ Athens, Greece
502.373.1201 Boehringer Ingelheim Investigational Site
Ioannina, Greece
502.373.1210 Boehringer Ingelheim Investigational Site
Kavala,greece, Greece
502.373.1224 Boehringer Ingelheim Investigational Site
Korinthos, Greece
502.373.1202 Boehringer Ingelheim Investigational Site
Melissia, Athens, Greece
502.373.1205 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
502.373.1213 Boehringer Ingelheim Investigational Site
Thessaloniki, Greece
502.373.1204 Boehringer Ingelheim Investigational Site
Veria, Greece
Hong Kong
502.373.0680 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0676 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0685 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0681 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
502.373.0677 Boehringer Ingelheim Investigational Site
Hong Kong, Hong Kong
Hungary
502.373.1230 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1227 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1231 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1232 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1242 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1235 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1239 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1233 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1244 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1237 Boehringer Ingelheim Investigational Site
Budapest, Hungary
502.373.1236 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
502.373.1240 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
502.373.1228 Boehringer Ingelheim Investigational Site
Kecskemet, Hungary
502.373.1241 Boehringer Ingelheim Investigational Site
Nyiregyhaza, Hungary
502.373.1226 Boehringer Ingelheim Investigational Site
Pecs, Hungary
502.373.1229 Boehringer Ingelheim Investigational Site
Siofok, Hungary
502.373.1238 Boehringer Ingelheim Investigational Site
Szeged, Hungary
502.373.1225 Boehringer Ingelheim Investigational Site
Szekesfehervar, Hungary
502.373.1234 Boehringer Ingelheim Investigational Site
Tatabanya, Hungary
502.373.1243 Boehringer Ingelheim Investigational Site
Veszprem, Hungary
Ireland
502.373.1717 Adelaide & Meath Hospitals
Dublin 24, Ireland
502.373.1714 Dept. of Clinical Pharmacology
Dublin 8, Ireland
502.373.1719 Pulmonary Function Laboratory
Dublin 9, Ireland
502.373.1720 Mallow General Hospital
Mallow, Ireland
Italy
502.373.1257 Ospedale "Mazzoni"
Ascoli Piceno, Italy
502.373.1259 Ospedale di Bentivoglio
Bentivoglio (BO), Italy
502.373.1255 Ospedale "S. Orsola Malpighi"
Bologna, Italy
502.373.1278 Ospedale Bellaria
Bologna, Italy
502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia
Brescia, Italy
502.373.1261 Ospedale Civile di Casarano
Casarano (LE), Italy
502.373.1252 Azienda Ospedaliera di Caserta
Caserta, Italy
502.373.1254 Ospedale di Città della Pieve
Città della Pieve (PG), Italy
502.373.1262 Arcispedale "S. Anna"
Ferrara, Italy
502.373.1250 Ospedale Civile "S. Polo"
Monfalcone (go), Italy
502.373.1279 Asl Na 1
Napoli, Italy
502.373.1266 Azienda Universitaria Policlinico "Federico II"
Napoli, Italy
502.373.1269 Università Federico II
Napoli, Italy
502.373.1267 Azienda Universitaria Policlinico II
Napoli, Italy
502.373.1264 Presidio Ospedaliero "Villa Sofia"
Palermo, Italy
502.373.1265 IRCCS - Policlinico S. Matteo
Pavia, Italy
502.373.1251 Policlinico Monteluce
Perugia, Italy
502.373.1258 Ospedale "R. Silvestrini"
Perugia, Italy
502.373.1274 Ospedale "R. Silvestrini"
Perugia, Italy
502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS
Pozzilli (IS), Italy
502.373.1268 Ospedale "S. Spirito"
Roma, Italy
502.373.1270 Policlinico di Tor Vergata
Roma, Italy
502.373.1263 Policlinico Umberto I
Roma, Italy
502.373.1273 A.O. "S. Camillo de Lellis"
Roma, Italy
502.373.1260 Ospedale "N. Melli"
S. Pietro Vernotico (BR), Italy
502.373.1256 Ospedale Civile SS. Annunziata - USL 1
Sassari, Italy
502.373.1277 A.S.O. "S. Giovanni Battista"
Torino, Italy
502.373.1272 Ospedale di Circolo di Varese
Varese, Italy
502.373.1271 Ospedale Civile
Venezia, Italy
502.373.1276 Ospedale Belcolle
Viterbo, Italy
Korea, Republic of
502.373.0763 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
502.373.0764 Boehringer Ingelheim Investigational Site
Kwang-ju, Korea, Republic of
502.373.0755 Boehringer Ingelheim Investigational Site
Pusan, Korea, Republic of
502.373.0761 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0756 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0750 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0760 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0753 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0757 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
502.373.0754 Boehringer Ingelheim Investigational Site
Taegu, Korea, Republic of
Malaysia
502.373.0736 Boehringer Ingelheim Investigational Site
Johor Baharu, Malaysia
502.373.0739 Boehringer Ingelheim Investigational Site
Kelantan, Malaysia
502.373.2707 Boehringer Ingelheim Investigational Site
Kelantan Darul Naim, Malaysia
502.373.0734 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
502.373.0732 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
502.373.0733 Boehringer Ingelheim Investigational Site
Penang, Malaysia
502.373.0731 Boehringer Ingelheim Investigational Site
Putrajaya, Malaysia
502.373.60001 Boehringer Ingelheim Investigational Site
Selangor, Malaysia
Mexico
502.373.0452 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0461 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0459 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0460 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0470 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0451 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0450 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
502.373.0458 Boehringer Ingelheim Investigational Site
Mexico, Mexico
502.373.0457 Boehringer Ingelheim Investigational Site
Mexico, Mexico
502.373.0454 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
502.373.0456 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
502.373.0453 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
Netherlands
502.373.1309 Boehringer Ingelheim Investigational Site
Amsterdam, Netherlands
502.373.1305 Boehringer Ingelheim Investigational Site
Beverwijk, Netherlands
502.373.1313 Boehringer Ingelheim Investigational Site
Den Bosch, Netherlands
502.373.1312 Boehringer Ingelheim Investigational Site
Den Haag, Netherlands
502.373.1302 Boehringer Ingelheim Investigational Site
Doetinchem, Netherlands
502.373.1304 Boehringer Ingelheim Investigational Site
Drachten, Netherlands
502.373.1301 Boehringer Ingelheim Investigational Site
Eindhoven, Netherlands
502.373.1318 Boehringer Ingelheim Investigational Site
Ermelo, Netherlands
502.373.1320 Boehringer Ingelheim Investigational Site
Ewijk, Netherlands
502.373.1310 Boehringer Ingelheim Investigational Site
Hengelo, Netherlands
502.373.1303 Boehringer Ingelheim Investigational Site
Hoorn, Netherlands
502.373.1322 Boehringer Ingelheim Investigational Site
Huizen, Netherlands
502.373.1300 Boehringer Ingelheim Investigational Site
Lichtenvoorde, Netherlands
502.373.1323 Boehringer Ingelheim Investigational Site
Losser, Netherlands
502.373.1307 Boehringer Ingelheim Investigational Site
Nieuwegein, Netherlands
502.373.1317 Boehringer Ingelheim Investigational Site
Rijswijk, Netherlands
502.373.1319 Boehringer Ingelheim Investigational Site
Roelofarendsveen, Netherlands
502.373.1308 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
502.373.1321 Boehringer Ingelheim Investigational Site
Spijkenisse, Netherlands
502.373.1311 Boehringer Ingelheim Investigational Site
Stadskanaal, Netherlands
502.373.1314 Boehringer Ingelheim Investigational Site
Tilburg, Netherlands
502.373.1316 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
502.373.1315 Boehringer Ingelheim Investigational Site
Velp, Netherlands
New Zealand
502.373.0500 Boehringer Ingelheim Investigational Site
Auckland, New Zealand
502.373.0502 Boehringer Ingelheim Investigational Site
Auckland 3, New Zealand
502.373.0507 Boehringer Ingelheim Investigational Site
Christchurch, New Zealand
502.373.0504 Boehringer Ingelheim Investigational Site
Hamiton, New Zealand
502.373.0506 Boehringer Ingelheim Investigational Site
Hasting, New Zealand
502.373.0501 Middlemore Hospital
Otahuhu Auckland, New Zealand
502.373.0503 Boehringer Ingelheim Investigational Site
Takapuna Auckland, New Zealand
502.373.0505 Tauranga Study Centre
Tauranga, New Zealand
Norway
502.373.20003 Boehringer Ingelheim Investigational Site
Fevik, Norway
502.373.20004 Fana Hjertesenter
Nesttun, Norway
502.373.20001 Stavanger Universitetssykehus
Stavanger, Norway
502.373.20002 Tvedestrand Legesenter
Tvedestrand, Norway
502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg
Tønsberg, Norway
Philippines
502.373.0702 De La Salle University Medical Center
Cavite, Philippines
502.373.0700 Philippine General Hospital
Manila, Philippines
502.373.0701 Manila Doctors Hospital, Room 3 Annex
Manila, Philippines
502.373.0705 The Medical City
Pasig City, Philippines
502.373.0704 National Kidney & Transplant Institute, Room 821
Quezon City, Philippines
502.373.0703 Philippine Heart Center
Quezon City, Philippines
Poland
502.373.1354 Boehringer Ingelheim Investigational Site
Bydgoszcz, Poland
502.373.1366 Boehringer Ingelheim Investigational Site
Czestochowa, Poland
502.373.1368 Boehringer Ingelheim Investigational Site
Gdynia, Poland
502.373.1365 Boehringer Ingelheim Investigational Site
Gdynia Redlowo, Poland
502.373.1359 Boehringer Ingelheim Investigational Site
Grojec, Poland
502.373.1369 Boehringer Ingelheim Investigational Site
Grudziadz, Poland
502.373.1375 Boehringer Ingelheim Investigational Site
Inowroclaw, Poland
502.373.1360 Boehringer Ingelheim Investigational Site
Jaroslawiec, Poland
502.373.1376 Boehringer Ingelheim Investigational Site
Katowice, Poland
502.373.1372 Boehringer Ingelheim Investigational Site
Katowice, Poland
502.373.1361 Boehringer Ingelheim Investigational Site
Kielce, Poland
502.373.1358 Boehringer Ingelheim Investigational Site
Lodz, Poland
502.373.1364 Boehringer Ingelheim Investigational Site
Lubartow, Poland
502.373.1374 Boehringer Ingelheim Investigational Site
Lubin, Poland
502.373.1367 Boehringer Ingelheim Investigational Site
Nowy Sacz, Poland
502.373.1356 Boehringer Ingelheim Investigational Site
Piotrkow Trybunalski, Poland
502.373.1370 Boehringer Ingelheim Investigational Site
Poznan, Poland
502.373.1357 Boehringer Ingelheim Investigational Site
Ruda Slaska, Poland
502.373.1352 Boehringer Ingelheim Investigational Site
Skierniewice, Poland
502.373.1362 Boehringer Ingelheim Investigational Site
Tarnow, Poland
502.373.1355 Boehringer Ingelheim Investigational Site
Tomaszow Mazowiecki, Poland
502.373.1353 Boehringer Ingelheim Investigational Site
Torun, Poland
502.373.1363 Boehringer Ingelheim Investigational Site
Warsaw, Poland
502.373.1351 Boehringer Ingelheim Investigational Site
Warsaw, Poland
502.373.1373 Boehringer Ingelheim Investigational Site
Wegrow, Poland
Portugal
502.373.1402 Hospital Garcia de Orta
Almada, Portugal
502.373.1400 Hospital Fernando Fonseca
Amadora, Portugal
502.373.1411 Hospital de Santa Cruz
Carnaxide, Portugal, 2799-523
502.373.1408 Hospitais da Universidade de Coimbra
Coimbra, Portugal
502.373.1406 Hospital Distrital de Faro Geral
Faro, Portugal
502.373.1403 Hospital de Santa Marta
Lisboa, Portugal
502.373.1409 Hospital de Santa Maria
Lisboa, Portugal
502.373.1401 Unidade Local de Saúde de Matosinhos
Matosinhos, Portugal
502.373.1410 Hospital de Santo António
Porto, Portugal
502.373.1407 Centro Hospitalar vila Nova de Gaia
Vila Nova de Gaia, Portugal
Puerto Rico
502.373.0215 Boehringer Ingelheim Investigational Site
Caguas, Puerto Rico
502.373.0267 Boehringer Ingelheim Investigational Site
Las Lomas, Puerto Rico
502.373.0190 Boehringer Ingelheim Investigational Site
Manati, Puerto Rico
502.373.0198 Boehringer Ingelheim Investigational Site
Orocovis, Puerto Rico
502.373.0262 Boehringer Ingelheim Investigational Site
Rio Piedras, Puerto Rico
Russian Federation
502.373.1425 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1426 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1427 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1428 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1429 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1430 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1433 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
502.373.1431 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
502.373.1432 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
Singapore
502.373.2706 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Singapore
502.373.0725 Boehringer Ingelheim Investigational Site
Singapore, Singapore
502.373.0726 Boehringer Ingelheim Investigational Site
Singapore, Singapore
Slovakia
502.373.1535 Boehringer Ingelheim Investigational Site
Bratislava, Slovakia
502.373.1529 Boehringer Ingelheim Investigational Site
Kosice, Slovakia
502.373.1540 Boehringer Ingelheim Investigational Site
Kosice, Slovakia
502.373.1538 Boehringer Ingelheim Investigational Site
Nitra, Slovakia
502.373.1545 Boehringer Ingelheim Investigational Site
Rimavska Sobota, Slovakia
South Africa
502.373.1553 Boehringer Ingelheim Investigational Site
Bellville, South Africa
502.373.1552 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
502.373.1561 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
502.373.1550 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
502.373.1554 Boehringer Ingelheim Investigational Site
Congella, South Africa
502.373.1551 Boehringer Ingelheim Investigational Site
Durban, South Africa
502.373.1560 Boehringer Ingelheim Investigational Site
Fiachrdtpark, Bloemfontein, South Africa
502.373.1563 Boehringer Ingelheim Investigational Site
George East, South Africa
502.373.1555 Boehringer Ingelheim Investigational Site
Park Town West, South Africa
502.373.1559 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
502.373.1562 Boehringer Ingelheim Investigational Site
Port Elizabeth, South Africa
502.373.1558 Boehringer Ingelheim Investigational Site
Soweto, South Africa
502.373.1557 Boehringer Ingelheim Investigational Site
Sunninghill, South Africa
502.373.1564 Boehringer Ingelheim Investigational Site
Sunninghill, South Africa
502.373.1556 Boehringer Ingelheim Investigational Site
Vanderbijlpark, South Africa
Spain
502.373.1582 Boehringer Ingelheim Investigational Site
Alcorcón (Madrid), Spain
502.373.1601 Boehringer Ingelheim Investigational Site
Alicante, Spain
502.373.1597 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1590 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1599 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1586 Boehringer Ingelheim Investigational Site
Barcelona, Spain
502.373.1595 Boehringer Ingelheim Investigational Site
Burjasot (Valencia), Spain
502.373.1585 Boehringer Ingelheim Investigational Site
Granada, Spain
502.373.1584 Boehringer Ingelheim Investigational Site
Granada, Spain
502.373.1576 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1580 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1592 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1578 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1589 Boehringer Ingelheim Investigational Site
Madrid, Spain
502.373.1594 Boehringer Ingelheim Investigational Site
Murcia, Spain
502.373.1577 Boehringer Ingelheim Investigational Site
Málaga, Spain
502.373.1596 Boehringer Ingelheim Investigational Site
Málaga, Spain
502.373.1593 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1579 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1598 Boehringer Ingelheim Investigational Site
Santiago de Compostela, Spain
502.373.1583 Boehringer Ingelheim Investigational Site
Sevilla, Spain
502.373.1591 Boehringer Ingelheim Investigational Site
Valencia, Spain
502.373.1575 Boehringer Ingelheim Investigational Site
Valencia, Spain
Sweden
502.373.1509 Hjärtsektionen / Med.kliniken
Göteborg, Sweden
502.373.1514 Hjärt/Kärlforskn.enheten
Göteborg, Sweden
502.373.1504 Capio Lundby sjukhus
Göteborg, Sweden
502.373.1501 Hjaertmottagningen
Helsingborg, Sweden
502.373.1505 Jakobsbergs sjukhus
Järfälla, Sweden
502.373.1502 Borgmästargaardens Läkarmottagning
Malmoe, Sweden
502.373.1508 Kolgahuset Läkargrupp
Malmö, Sweden
502.373.1506 Hjärtmottagningen
Malmö, Sweden
502.373.1507 Kardiologiska kliniken
Malmö, Sweden
502.373.1511 Sjuntorps Vaardcentral
Sjuntorp, Sweden
502.373.1503 Källtorps Vaardcentral
Trollhättan, Sweden
502.373.1512 Vännäs Vaardcentral
Vännäs, Sweden
Switzerland
502.373.1625 Boehringer Ingelheim Investigational Site
Basel, Switzerland
502.373.1632 Boehringer Ingelheim Investigational Site
Bellinzona, Switzerland
502.373.1634 Boehringer Ingelheim Investigational Site
Bern, Switzerland
502.373.1627 Boehringer Ingelheim Investigational Site
Biel/Bienne, Switzerland
502.373.1631 Boehringer Ingelheim Investigational Site
Chur, Switzerland
502.373.1633 Boehringer Ingelheim Investigational Site
Kreuzlingen, Switzerland
502.373.1639 Boehringer Ingelheim Investigational Site
Lausanne, Switzerland
502.373.1629 Boehringer Ingelheim Investigational Site
Lugano, Switzerland
502.373.1628 Boehringer Ingelheim Investigational Site
St. Gallen, Switzerland
502.373.1637 Boehringer Ingelheim Investigational Site
Zürich, Switzerland
Taiwan
502.373.0780 Boehringer Ingelheim Investigational Site
Changhua, Taiwan
502.373.0779 Boehringer Ingelheim Investigational Site
Chia-Yi, Taiwan
502.373.0783 Boehringer Ingelheim Investigational Site
Hualien, Taiwan
502.373.0778 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
502.373.0776 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
502.373.0775 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
502.373.0777 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
502.373.0782 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
502.373.0781 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
Thailand
502.373.0801 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0802 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0808 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0806 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0805 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0804 Boehringer Ingelheim Investigational Site
Bangkok, Thailand
502.373.0803 Boehringer Ingelheim Investigational Site
Khon Kaen, Thailand
502.373.0807 Boehringer Ingelheim Investigational Site
Nonthaburi, Thailand
Turkey
502.373.1652 Cukurova Universitesi Tip Fakultesi
Adana, Turkey
502.373.1651 Cukurova Universitesi Tip Fakultesi
Adana, Turkey
502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü
Ankara, Turkey
502.373.1656 Baskent Universitesi Tip Fakultesi
Ankara, Turkey
502.373.1659 Ankara Universitesi Tip Fakultesi
Ankara, Turkey
502.373.1655 Cerrahpasa Universitesi Tip Fakultesi
Istanbul, Turkey
502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi
Istanbul, Turkey
502.373.1657 Haseki Hastanesi
Istanbul, Turkey
502.373.1658 Ege Universitesi Tip Fakultesi
Izmir, Turkey
502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali
Kayseri, Turkey
Ukraine
502.373.1731 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk, Ukraine
502.373.1730 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk, Ukraine
502.373.1733 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
502.373.1728 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
502.373.1732 Boehringer Ingelheim Investigational Site
Kharkov, Ukraine
502.373.1726 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1725 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1729 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1734 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
502.373.1727 Boehringer Ingelheim Investigational Site
Kiev, Ukraine
United Arab Emirates
502.373.1680 Boehringer Ingelheim Investigational Site
Abu Dhabi, United Arab Emirates
502.373.1679 Boehringer Ingelheim Investigational Site
Dubai, United Arab Emirates
502.373.1675 Boehringer Ingelheim Investigational Site
Dubai, United Arab Emirates
502.373.1677 Boehringer Ingelheim Investigational Site
Sharjah, United Arab Emirates
United Kingdom
502.373.1698 Boehringer Ingelheim Investigational Site
Aberdeen, United Kingdom
502.373.1706 Boehringer Ingelheim Investigational Site
Bathampton, United Kingdom
502.373.1690 Boehringer Ingelheim Investigational Site
Belfast, United Kingdom
502.373.1694 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
502.373.1707 Boehringer Ingelheim Investigational Site
Brighton, United Kingdom
502.373.1703 Boehringer Ingelheim Investigational Site
Cardiff, United Kingdom
502.373.1709 Boehringer Ingelheim Investigational Site
Chichester, United Kingdom
502.373.1701 Boehringer Ingelheim Investigational Site
Derby, United Kingdom
502.373.1705 Boehringer Ingelheim Investigational Site
Gateshead, United Kingdom
502.373.1710 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
502.373.1700 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife, United Kingdom
502.373.1691 Boehringer Ingelheim Investigational Site
Leeds, United Kingdom
502.373.1699 Boehringer Ingelheim Investigational Site
Leicester, United Kingdom
502.373.1702 Boehringer Ingelheim Investigational Site
Lincoln, United Kingdom
502.373.1697 Boehringer Ingelheim Investigational Site
Liverpool, United Kingdom
502.373.1695 Boehringer Ingelheim Investigational Site
London, United Kingdom
502.373.1693 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
502.373.1708 Boehringer Ingelheim Investigational Site
Portadown, County Atrim, United Kingdom
502.373.1692 Boehringer Ingelheim Investigational Site
Rugby, United Kingdom
502.373.1696 Boehringer Ingelheim Investigational Site
Sheffield, United Kingdom
502.373.1704 Boehringer Ingelheim Investigational Site
Stirling, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Additional Information:
No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00153101     History of Changes
Obsolete Identifiers: NCT00034931
Other Study ID Numbers: 502.373
Study First Received: September 9, 2005
Results First Received: June 15, 2009
Last Updated: May 13, 2014
Health Authority: Argentina: National Administration of Medicines, Food and Medical Technology
Australia: Responsilble Ethics Committee
Austria: Ministry for Social Security and Generations
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Brazil: National Health Surveillance Agency
Canada: Health Canada
China: Food and Drug Administration
Czech Republic: State Institute for Drug Control (SUKL)
Denmark: Danish Medicines Agency
Finland: Finnish Medicines Agency
France: AFFSAPS
Germany: Federal Institute for Drugs and Medical Devices
Great Britain: MHRA
Greece: HELLENIC REPUBLIC MINISTRY OF HEALTH AND WELFARE NATIONAL ORGANISATION OF MEDICINES (EOF)
Hong Kong: Dept. of Health, Hong Kong
Hungary: National Institute of Pharmacy (OGYI), H-1051 Budapest
Ireland: The Irish Medicines Board
Italy: Comitato Etico delle Aziende Sanitarie della Regione Umbria
Korea, Republic of: Korea Food and Drug Administration (KFDA)
Malaysia: Drug Control Authority
Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
New Zealand: Multicentre Ethics Committee/Medsafe
Norway: Norwegian Medicines Agency (Statens Legemiddelverk)
Philippines: Bureau of Pharmaceutical Affairs, Department of Health
Poland: CEBK, Warsaw
Portugal: INFARMED, National Authority of Medicines and Health Products, IP
Russia: Ministry of Health of the Russian Federation
Singapore: Centre of Drug Administration
Slovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26
South Africa: Medicines Control Council
Spain: Ministry of Health
Sweden: Medical Product Agency
Switzerland: Swissmedic Schweizerisches Heilmittelinstitut (Swiss Agency for Therapeutic Products)
Taiwan: Dept. of Health, Executive Yuan, Taiwan
Thailand: Bureau of Pharmaceutical Affairs, Department of Health
Turkey: Ministry of Health Central Ethics Committee
Ukraine: State Pharmacology Centre of the Ministry of Health of Ukraine
United Arab. Emirates: Medical Affairs Department of Health and Medical Services, General Authority Health Services, Ministry of Health for Northern Emirates
United States: Food and Drug Administration

Additional relevant MeSH terms:
Cardiovascular Diseases
Ramipril
Telmisartan
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers

ClinicalTrials.gov processed this record on July 31, 2014